| Keywords: |
adult; child; leukemia; unclassified drug; histone deacetylase inhibitor; lenalidomide; prednisone; allogeneic stem cell transplantation; doxorubicin; interferon; disease classification; clinical trials as topic; note; gemcitabine; combined modality therapy; antineoplastic agent; ultraviolet radiation; bortezomib; multiple cycle treatment; antineoplastic combined chemotherapy protocols; inflammation; cyclophosphamide; vincristine; hematopoietic stem cell transplantation; peripheral t cell lymphoma; t cell lymphoma; lymphoma, t-cell; tumor virus infections; large cell lymphoma; cancer classification; immune deficiency; immunocompromised host; drugs, investigational; romidepsin; transplantation, autologous; clofarabine; pralatrexate; retinoid; sgn 35; epstein barr virus; retrovirus infection; topical treatment; aminopterin; depsipeptides; multicenter studies as topic
|
